ChemoFx assay (Precision Therapeutics Inc.) for prediction of response to chemotherapy

Record ID 32011001350
English
Authors' objectives:

Cancer is the second leading cause of death in the United States, despite the availability of a wide range of effective chemotherapy drugs. Physicians generally base decisions on chemotherapy regimens for a particular patient on clinical evidence that has accumulated on the typical drug sensitivity of the type of cancer being treated. This generalized approach often, but not always, leads to a partial or complete response. Information about the responsiveness of a patient's cancer to certain drugs (chemosensitivity) would help to guide treatment decisions, and potentially improve health outcomes. For chemosensitivity testing, cancer cells are removed from a patient, grown in a laboratory, and exposed to various chemotherapeutic drugs. In some cases, the cancer cells show unexpected behavior, such as resistance to the drugs usually used to treat that particular cancer and sensitivity to the drugs that are not usually used. In theory, the drugs that have the greatest effect on a patient's cancer cells in the laboratory will have the greatest effect on the cancer cells in the patient.

Details
Project Status: Completed
Year Published: 2011
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Antineoplastic Combined Chemotherapy Protocols
  • Survival Rate
  • Treatment Outcome
Contact
Organisation Name: HAYES, Inc.
Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name: saleinfo@hayesinc.com
Contact Email: saleinfo@hayesinc.com
Copyright: 2011 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.